

cbadm

center for behavioral &
addiction medicine

ANNUAL REPORT

July 2021 - June 2022



A Letter from our Executive Director



The UCLA Center for Behavioral and Addiction Medicine is a network of people from different backgrounds, disciplines and interests. We share a commitment to leverage science to address suffering for people living with addictions and a range of physical and psychological comorbidities linked to addictive diseases. The state of CBAM is unbelievably strong: CBAM members lead or co-lead 28 studies this year. Not only is this a high-water mark collectively, but CBAM members have also brought in over \$10 million in research

funding, a banner year for sure!

The reach of the work at CBAM is broad, spanning three different research institutes and multiple research networks at NIH. They include NAIAD (HPTN, HVTN), NIMH (P30 AIDS Research Centers), and NIDA (CTN, mSTUDY/C3PNO). The 28 current studies range from multi-site RCTs (randomized clinical trials) to large cohort studies to single site RCTs and pilot studies. They touch on multiple topics including addictions (N=12), HIV (N=10), intersectional addiction and HIV (N=5), and one infectious diseases study (COVID-19 vaccines).

The volume of our collective voice at CBAM also grows with this exceptional productivity and impact. CBAM scientists and staff are tapped to advise local, regional, national and multi-national efforts that are based in evidence with a mission to improve the health of people living at the intersection of addictions, HIV and comorbid conditions.


In looking to the next year, I believe it will be challenging to complete all of the tasks involved in this ambitious research plan and do it well. But I have no fear in the path forward. I'm immensely proud of this group and our shared commitment to doing what's right, to make things better and to be kind. Each day I believe we distinguish CBAM and ourselves as an outstanding example of best practice when taking research to communities – making sure that every day we move together with all of our members, stakeholders and participants to conduct the work in ways that measurably repair pieces of this world, which are so broken.

A handwritten signature in black ink, appearing to be 'S. S. S.' or similar.

Research Highlights



In pursuit of our mission, CBAM conducts research on medical, behavioral, and combination approaches to the prevention and treatment of chronic illnesses, with a particular focus on addiction and HIV. We stress the values of integrity and scientific rigor in the conduct of our research and work closely with the communities we serve to ensure that the best of care is given. The following pages highlight our research activities over the past year.





Human Laboratory Study of ASP8062 for Alcohol Use Disorder/HLAB003

The primary objective of this study is to evaluate the effects of ASP8062 on alcohol craving among people with moderate to severe alcohol use disorder (AUD). Secondary objectives include evaluation of this compound on reduction of alcohol consumption, alcohol craving, cigarette smoking and nicotine use, mood, sleep, alcohol use negative consequences, study retention, and safety and tolerability throughout the last four weeks of the treatment phase of the study. This study is led by our colleague Dr. Lara Ray and her team in the UCLA Addictions Lab.

HIV Vaccine Trial



Development of effective vaccines to protect individuals against HIV is a challenging and growing public health priority. The HVTN's mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally. The HVTN 302 study is a phase 1 clinical trial looking to evaluate the safety and immunogenicity (how the immune system responds) to three different HIV trimer mRNA vaccines in healthy, HIV uninfected adults. Our UCLA Vine Street Clinic Medical Director, Dr. Jesse Clark, leads the study locally and serves as the Protocol Chair of the trial for the HIV Vaccine Trials Network.

IMSTI

Methamphetamine (MA) use is common among men who have sex with men (MSM) and is an important driver of the HIV/STI epidemic. Understanding the biological and behavioral risk factors that drive ongoing HIV/STI transmission among MA-using MSM is critical to designing potent HIV prevention interventions. This study will evaluate whether methamphetamine use and/or sexually transmitted infections influence levels of inflammatory markers (cytokines) in the blood and in the rectum. The study uses contingency management and will include visits three times a week over 8 weeks. Participants will also be asked to complete surveys, provide biological samples, and have urine tested for the presence of drugs. They will be offered a prescription for HIV pre-exposure prophylaxis at enrollment.

Study Results

Equity and Access: A Roadmap to Improving Vaccination Equity in South Los Angeles



CBAM and Charles R. Drew University of Medicine and Science, in collaboration with the California Community Foundation have published a report that provides insights on how to reach communities of color to educate, build trust, and disseminate COVID-19 vaccines in South Los Angeles, given historical experiences generating medical mistrust. This community-based study identified inequities and how these inequities interfere with access to COVID-19 vaccines for Black and Latina/o/x communities in South Los Angeles. The project focused on three goals:

- Facilitate community, public, private, and governmental partnerships to reduce COVID-19 vaccine inequity.
- Educate communities of color in South LA about the COVID-19 vaccines through virtual town halls.
- Navigate communities of color in South LA on how to access available COVID-19 vaccines.

The findings in this report are intended to guide efforts to enhance engagement with key stakeholders, and help build the capacity of community and public agencies to provide timely and effective responses to future public health emergencies. Click [here](#) to access the report and community resource guide.

California Bridge Patient Outcomes Research Evaluation Study

California Bridge provides technical assistance and support to hospitals and emergency rooms to become primary access points for medication assisted treatment (MAT) in their communities. As previously reported, we are working with Public Health International (PHI) on research related to CA Bridge. Recent findings showed the success of implementing buprenorphine treatment in Emergency Departments using a low-threshold approach and active navigation to link patients to follow up treatment in an outpatient setting. Details can be found in the following publication.

- Snyder H, Kalmin MM, Moulin A, Campbell A, Goodman-Meza D, Padwa H, Clayton S, Speener M, Shoptaw S, Herring AA, 2021. Rapid adoption of low-threshold buprenorphine treatment at California emergency departments participating in the CA Bridge Program. *Ann. Emerg. Med.* 78, 759-772.

Additional papers published this year from Bridge Program data include:

- Kalmin MM, Goodman-Meza D, Anderson E, Abid A, Speener M, Snyder H, Campbell A, Moulin A, Shoptaw S, Herring AA, 2021. Voting with their feet: Social factors linked with treatment for opioid use disorder using same-day buprenorphine delivered in California hospitals. *Drug Alcohol Depend.* Mar. 18,
 - Hern HG, Goldstein D, Kalmin M, Kidane S, Shoptaw S, Tzvieli O, Herring AA, 2021. Prehospital initiation of buprenorphine Treatment for opioid use disorder by paramedics. *Prehosp. Emerg. Care* 22, 1-7.
 - Hailozian C, Luffig J, Liang A, Outhay M, Ullal M, Anderson ES, Kalmin M, Shoptaw S, Greenwald MK, Herring AA, 2021. Synergistic effect of ketamine and buprenorphine observed in the treatment of buprenorphine precipitated opioid withdrawal in a patient with fentanyl use. *J. Addict. Med.* Nov 16.
- 



The Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) promotes collaborative research, networking, and capacity building among HIV researchers and communities in efforts to eliminate new HIV infections and health disparities among key populations.

Ending the HIV Epidemic

The Ending the HIV Epidemic (EHE) was launched in 2019 with the aim of ending the HIV epidemic in the United States by 2030. CHIPTS faculty have received multiple grants over the past three years to advance these goals. Recent publications from this work include:

- Üsküp DK, Nieto O, Rosenberg-Carlson E, Lee SJ, Milburn NG, Brooks RA, 2022. Acceptability and appropriateness of digital PrEP interventions for Black and Latina cisgender women: Perspectives from service providers in Los Angeles County. *J. Acquired Immune Defic. Syndr.* 90(S1):S134-S140.
- Jolayemi, O, Bogart, L M, Storholm, E D, Goodman-Meza, D, Rosenberg-Carlson, E, Cohen, R, Kao, U, Shoptaw, S, Landovitz, RJ, 2022. Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. *PLoS One* 17(2).
- Brooks, RA, Nieto, O, Santillan, M, Jr, Landrian, A, Fehrenbacher, AE, Cabral, A, 2022. Beyond HIV prevention: Additional individual and community-level benefits of PrEP among Latino gay and bisexual men. *PLoS One* June 13, 17(6).

GRANT RENEWAL
We successfully renewed the CHIPTS grant this year for another 5-year period. CHIPTS is now in its 26th year!

KICK START PROGRAM
CHIPTS launched a Kick Start program to support the development of new research ideas and other projects to address emerging issues and needs of communities most impacted by HIV. The program has a strong focus on community collaborations and partnerships.

PILOT STUDIES
CHIPTS awards pilot funding each year to young investigators. The program provides individualized, mentorship from faculty researchers. Successful completion of a pilot study is expected to enhance investigators' potential to develop into productive, independent research scientists. Five pilots were funded this year to investigators at UCLA, RAND, San Diego State University, and the University of Cape Town. Studies target people leaving jail, pregnant and breastfeeding women, minority men, and people living with HIV.

GRAND ROUNDS
We took the lead on organization of the UCLA HIV Grand Rounds, which consists of hour-long lunchtime lectures that are delivered by invited guests or distinguished faculty on a broad range of HIV-related topics.


NIDA Summer Intern

CBAM participated in the National Institute on Drug Abuse Summer Research Internship Program, which supports undergraduate students with a focus on increasing representation of underrepresented populations in addiction research. We've been a participant in this program since 2007, mentoring over a dozen students.

Substance use outcomes in African American men with histories of incarceration

KUSUM BASNET
SUMMER 2022
NIDA INTERNSHIP

NIDA Summer Research Internship Program Framework: Hub and Spoke Model



This year's intern was Kusum Basnet, a recent UCLA graduate interested in pursuing a medical degree. Kusum's summer project included a literature review examining substance use outcomes in African American men with histories of incarceration.

Media



Dr. Shoptaw was quoted in a front page LA Times article "Can a Target gift card help you stay off meth? This L.A. program is trying it".

"This isn't just paying people to do what they should do," said Steve Shoptaw, a UCLA professor of family medicine who has researched treatments for stimulant use disorder. "This is an intervention that actually stimulates the brain to work in different ways so that their goals are met."

Click [here](#) to read the full article.



Dr. Jesse Clark was interviewed by NPR about his experience with both the COVID and HIV pandemics and how development of the COVID vaccines has accelerated the pace of development of an HIV vaccine. Click [here](#) to learn more.



The Carlat Psychiatry Podcast, a digital program that reviews evidence-based psychiatry, provided an overview of the history and pharmacology of methamphetamine use disorder. In this segment, the ADAPT-2 trial published in *The New England Journal of Medicine* (co-authored by Dr. Shoptaw) was discussed. To hear the podcast and learn more about the basics of methamphetamine use disorder and the current novel treatment options in consideration, [click here](#)

Scientific Publications



As scientists, our biggest impact comes from the knowledge we generate and share. It's that knowledge of what works, what doesn't and why that leads to better policy, better medicine and better lives for those we serve. We published more than 50 papers this past year. Highlights include:


- Üsküp, D., Jolayemi, O., Mays M., V., Harawa, N., Shover, C., Branch, C., Sanchez, E., Kao, U., Shoptaw, S., 2022. [Equity and access: A roadmap to improving vaccination equity in South Los Angeles](#). CBAM, May.
- Lake, M. T., Krishnamurti, T., Murtaugh, K. L., van Nunen, L. J., Stein, D. J., Shoptaw, S., 2022. [Decision-making tendencies and voucher spending independently support abstinence within contingency management for methamphetamine use disorder](#). Exp. Clin. Psychopharmacol. Apr 28.
- Goodman-Meza, D., Arredondo, J., Slim, S., Angulo, L., Gonzalez-Nieto, P., Loera, A., Shoptaw, S., Cambou, M. C., Pitpitan, E. V., 2022. [Behavior change after fentanyl testing at a safe consumption space for women in Northern Mexico: A pilot study](#). Int. J. Drug Pol. 106, 103745.
- Giang, L. M., Trang, N. T., Diep, N. B., Thuy, D., Thuy, D. T., Hoe, H. D., Van, H., Truc, T. T., Nguyen, H. H., Lai, N. L., Linh, P., Vi, V., Reback, C. J., Leibowitz, A., Li, L., Lin, C., Li, M., Do Van Dung, Shoptaw, S., 2022. [An adaptive design to screen, treat, and retain people with opioid use disorders who use methamphetamine in methadone clinics \(STAR-OM\): study protocol of a clinical trial](#). Trials 23, 342.
- Satcher, M. F., Segura, E. R., Silva-Santisteban, A., Reisner, S. L., Perez-Brumer, A., Lama, J. R., Operario, D., & Clark, J. L. 2022. [Exploring Contextual Differences for Sexual Role Strain Among Transgender Women and Men Who Have Sex with Men in Lima, Peru](#). Arch. Sex. Behav., 51(4), 1977–1991.

To learn more and to read summaries of each article, visit our [website](#).

Dr. Shoptaw named Editor in Chief

Our Director, Dr. Steven Shoptaw, was named Editor in Chief of the Journal Drug and Alcohol Dependence, which is currently on of the top rated addiction journal in the world.

Andraya Dolbee also joined our team this year as Editorial Office Manager.



Our Team

CHIPTS World AIDS Day 2021

Our CHIPTS team hosted World AIDS Day (WAD) events throughout Los Angeles County, offering free ice-cream, HIV/AIDS-related resources, and safer sex supplies to all attendees. Below are CHIPTS staff and collaborators at Wilson Plaza on the UCLA campus and staff and faculty from our mobile clinic at the WAD event in Long Beach. There was also an event held at Charles Drew University.



HIV Prevention Trials Network 2022 Annual Meeting

Our UCLA Vine Street Clinic team, including our mobile clinic staff, attended this year's HPTN annual conference in Washington DC. This was the first time the event was held in person since the pandemic began. Staff were able to take a selfie with Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Disease. They were also able to find time for a team dinner.



Clinic Staff Picnic

The UCLA Vine Street Clinic and mobile clinic staff and faculty also gathered this summer for a staff picnic. The day included lunch and a water balloon toss. Not pictured is the good natured water fight that followed. After more than two years working side-by-side, every day, fully masked, the event was a much needed way to let off a little steam.





CENTER FOR BEHAVIORAL & ADDICTION MEDICINE
Financial Statement for Fiscal Year 2020/2021
(July 1, 2021 through June 30, 2022)

INCOME	<u>Permanently</u>	<u>Temporarily</u>	Unrestricted	Total	FY 2020/2021
	<u>Restricted</u>	<u>Restricted</u>			
Federal Contracts & Grants	\$ 9,271,154	\$ -	\$ -	\$ 9,271,154	\$ 8,724,054
State/Local Contracts & Grants	\$ 109,611	\$ -	\$ -	\$ 109,611	\$ -
Subcontracts	\$ 986,109	\$ -	\$ -	\$ 986,109	\$ 1,011,357
Corporations	\$ -	\$ -	\$ -	\$ -	\$ -
Foundations	\$ -	\$ -	\$ -	\$ -	\$ 170,000
Individuals	\$ -	\$ -	\$ 20,497	\$ 20,497	\$ -
UC Funds	\$ 20,000	\$ -	\$ 196,370	\$ 216,370	\$ 195,946
Clinical Services Income	\$ -	\$ -	\$ 245,044	\$ 245,044	\$ 248,647
TOTAL INCOME	\$ 10,386,874	\$ -	\$ 461,911	\$ 10,848,785	\$ 10,350,004
EXPENSES					
Academic Salaries				\$ 634,867	\$ 526,249
Staff Salaries				\$ 2,320,327	\$ 1,899,712
Fringe Benefits				\$ 1,159,794	\$ 878,737
Stipends - Postdoctoral Fellows				\$ -	\$ -
Stipends - Interns				\$ 2,400	\$ 2,400
Consultants/Guest Lecturers				\$ 132,111	\$ 129,788
Employee Training/Certifications/Licenses/Memberships				\$ 3,794	\$ 2,975
Subawards				\$ 299,706	\$ 259,950
Funds Transferred to Other Departments (Direct)				\$ 1,191,270	\$ 963,309
Space Rental				\$ 176,661	\$ 183,980
Alterations/Renovations				\$ -	\$ 119,547
Communications				\$ 57,180	\$ 56,383
Clinic Operations				\$ 64,681	\$ 70,852
Vehicle Purchase				\$ -	\$ 33,961
Vehicle Operating Costs				\$ 56,875	\$ 11,843
General Supplies & Equipment				\$ 10,698	\$ 8,785
Computers, Software & Computer Supplies				\$ 33,460	\$ 32,413
Medical Supplies				\$ 31,020	\$ 31,362
Project-Related Supplies				\$ 56,442	\$ 61,367
Travel and Events				\$ 55,250	\$ 7,003
Postage/Courier				\$ 35,592	\$ 13,369
Print, Copy & Media Services				\$ 13,801	\$ 5,976
Publication Fees				\$ -	\$ 15,610
Transcription Services				\$ 6,814	\$ 5,410
Recruitment Ads				\$ 37,769	\$ 17,034
Lab Services				\$ 100,650	\$ 47,065
Pharmacy				\$ 40,991	\$ 15,663
Inpatient Care				\$ 159,465	\$ 4,177
Participant Incentives				\$ 214,424	\$ 263,149
Website Services				\$ 2,854	\$ -
Miscellaneous				\$ 14,404	\$ 5,236
Indirect Charges				\$ 1,747,887	\$ 1,353,402
				\$ -	\$ -
TOTAL EXPENSES				\$ 8,661,185	\$ 7,026,704
NET INCOME (LOSS) YTD*				\$ 2,187,600	\$ 3,323,300

This document was generated internally. It is not an audited financial statement.

**The net balance is primarily restricted project funding that will carryover into the next fiscal year.*



About CBAM

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illness, especially in communities with health disparities.

CBAM works at the intersection of academia and community with a focus on treating addiction and preventing the spread of HIV. We are housed in the UCLA Department of Family Medicine. Our faculty include:



Steven Shoptaw, PhD

Executive Director, UCLA Center for Behavioral & Addiction Medicine
PI/Director, UCLA Center for HIV Identification, Prevention & Treatment Services
Professor and Vice Chair of Research, UCLA Department of Family Medicine
Professor, Department of Psychiatry and Biobehavioral Sciences
Honorary Professor, University of Cape Town Department of Psychiatry and Mental Health



Jesse Clark, MD, MSc

Associate Professor in Residence, UCLA Department of Medicine, Division of Infectious Disease
Associate Professor in Residence, UCLA Department of Family Medicine
Medical Director, UCLA Vine Street Clinic
Director, South American Program in HIV Prevention Research (SAPHIR)



Oladunni Adeyiga, MD

Assistant Clinical Professor, UCLA Department of Medicine, Division of Infectious Disease



Cherie Blair, MD

Assistant Clinical Professor, UCLA Department of Medicine, Division of Infectious Disease



Ron Brooks, PhD

Assistant Professor, UCLA Department of Family Medicine



David Goodman-Meza, MD, MAS

Assistant Clinical Professor, UCLA Department of Medicine, Division of Infectious Disease



Timothy Hall, MD, PhD, FAPA FASAM

Assistant Clinical Professor, UCLA Department of Family Medicine



Mariah Kalmin, PhD

Assistant Research Professor



Michael Li, PhD

Assistant Professor, UCLA Department of Family Medicine




Dilara Uskup, PhD

Assistant Professor, UCLA Department of Family Medicine



Show your support!

To help support this life-changing work, visit us at <http://www.uclacbam.org/about-us/donate/> or call (310) 794-0645 to speak with our Administrative Director. More than 92% of every donation goes directly to serve our mission and all donations are tax deductible. Naming opportunities are available!



Contact Us!

UCLA Center for Behavioral &
Addiction Medicine
10880 Wilshire Blvd., Ste. 1800
Los Angeles, CA 90024
(310) 794-0619
cbam@mednet.ucla.edu
cbam.ucla.edu